Kiniksa Pharmaceuticals International, plc KNSA
75.08
(0.26)
(0.35%)
as of 25 Sep
- Market cap
- $5.9B
- P/E
- 70.2×
Follow KNSA
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
| P/E ratio |
+8 more quarters Free account |
79.24 | 51.56 | 49.13 | 59.77 |
| P/S ratio | 4.85 | 4.52 | 4.89 | 5.90 | |
| P/FCF ratio | 28.49 | 22.42 | 22.42 | 27.12 | |
| P/Operating CF | 86.15 | 56.79 | 73.39 | 105.12 | |
| P/B ratio | 5.42 | 5.39 | 6.08 | 7.58 | |
| Price to Tangible BV | 5.58 | 5.54 | 6.24 | 7.76 | |
| EV/Sales | 4.26 | 3.91 | 4.27 | 5.27 | |
| EV/EBITDA | 64.30 | 33.60 | 33.89 | 43.46 | |
| EV/Operating CF | 24.78 | 19.18 | 19.39 | 23.98 | |
| EV/FCF | 25.03 | 19.39 | 19.57 | 24.25 | |
| Quick Ratio | 3.27 | 3.09 | 3.14 | 3.21 | |
| Current Ratio | 3.85 | 3.79 | 3.79 | 3.90 | |
| Net Debt/EBITDA | (14.43) | (20.46) | (15.74) | (19.01) | |
| Debt/Assets | 0.00% | 0.00% | 0.00% | 0.00% | |
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | |
| Asset Turnover | 0.94 | 1.01 | 1.06 | 1.08 | |
| Operating CF/Net income | 1.83 | 3.80 | 2.22 | 1.86 | |
| Capex/Depreciation | (1.75) | (1.36) | (0.34) | (1.40) | |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 | |
| Research and Development Expense of Revenue | 13.36% | 17.12% | 12.82% | 16.79% | |
| Selling, General and Administrative Expense of Revenue | 27.15% | 28.09% | 28.54% | 26.22% | |
| Intangible Assets out of Total Assets | 0.02 | 0.02 | 0.02 | 0.02 | |
| Share Based Compensation of Revenue | 5.61% | 5.06% | 4.69% | 4.78% | |
| Graham Net Nets | 0.10 | 0.11 | 0.10 | 0.09 | |
| Graham Number | 8.89 | 11.73 | 13.21 | 14.25 | |
| Earnings Yield | 1.26% | 1.94% | 2.04% | 1.67% | |
| Free Cash Flow Yield | 3.51% | 4.46% | 4.46% | 3.69% | |
| Revenue per Share | 2.42 | 2.72 | 2.80 | 3.14 | |
| Operating CF per Share | 0.45 | 0.73 | 0.66 | 0.61 | |
| Capex per Share | (0.01) | (0.01) | 0.00 | (0.01) | |
| Free Cash Flow per Share | 0.44 | 0.72 | 0.65 | 0.60 | |
| Cash per Share | 4.71 | 5.58 | 6.12 | 6.78 | |
| Shareholders Equity per Share | 7.17 | 7.65 | 7.92 | 8.43 | |
| Interest Debt per Share | 0.00 | 0.00 | 0.00 | 0.00 | |
| Book value per Share | 7.17 | 7.65 | 7.92 | 8.43 | |
| Free Cash Flow | 33.01 | 53.26 | 50.04 | 46.53 | |
| Working Capital | 351.94 | 387.99 | 437.56 | 497.39 | |
| Capital Expenditures | (0.67) | (0.63) | (0.16) | (0.66) | |
| Net Current Asset Value | 298.58 | 331.15 | 374.58 | 426.67 | |
| EV/EBIT | 66.81 | 34.27 | 34.50 | 44.24 | |
| Capex to Sales | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Profit Margin | 10.19% | 7.02% | 10.54% | 10.44% | |
| Price to Operating Income | 76.04 | 39.64 | 39.52 | 49.49 | |
| Other line items | |||||
| Average Receivables | 38.32 | 28.66 | 31.64 | 27.70 | |
| Average Payables | 7.24 | 2.03 | 13.19 | 10.68 | |
| Average Inventory | 35.04 | 40.63 | 47.61 | 59.56 | |
| Average Assets | 633.82 | 672.09 | 712.30 | 778.63 | |
| Average Common Equity | 486.19 | 503.02 | 531.59 | 574.58 |
Columns are period end dates